Literature DB >> 7760434

Etoposide-based combination chemotherapy in malignant histiocytosis.

F R Lin1, E G Yao.   

Abstract

We investigated the responses of patients with malignant histiocytosis (MH) to the treatment of epotoside-based regimen. Of 11 evaluable cases, 9 (81.8%) achieved complete remission and 1 partial remission. 7 complete remission cases (77.7%) received only one therapeutic course. The side effects were mild and well-tolerated. We conclude that etoposide-containing regimen is highly effective and can be used as first-line treatment for MH and is worthy of further study.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7760434     DOI： 10.1007/BF02897674

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN： 0257-716X


  5 in total

Review 1.  The biology of macrophages: I. General principles and properties.

Authors:  R Seljelid; T Eskeland
Journal:  Eur J Haematol       Date:  1993-11       Impact factor: 2.997

2.  The treatment of malignant histiocytosis.

Authors:  A Tseng; C N Coleman; R S Cox; T V Colby; R R Turner; S J Horning; S A Rosenberg
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

3.  Malignant histiocytosis in childhood: clinical study and therapeutic results in 22 cases.

Authors:  J M Zucker; J M Caillaux; D Vanel; R Gerard-Marchant
Journal:  Cancer       Date:  1980-06-01       Impact factor: 6.860

4.  Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia.

Authors:  J M Rowe; A Y Chang; J M Bennett
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

5.  VP-16-213 (etoposide): the mandrake root from Issyk-Kul.

Authors:  N J Vogelzang; D Raghavan; B J Kennedy
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.